Recorded device evidence

Powder Free Nitrile Examination Gloves (Violet, Black, Green), Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Select Other Drugs (K243959): indications, design and recorded evidence

The acquired K243959 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 11 selected decisions under primary code LZC. 11 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K243959 ↗ · this pagePowder Free Nitrile Examination Gloves (Violet, Black, Green), Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Select Other Drugs2024-12-23 → 2025-02-2463Traditional
K252313 ↗Cardinal Health Nitrile Examination Gloves Extended Cuff2025-07-25 → 2026-01-14173Traditional
K221157 ↗JR Medic2022-04-21 → 2022-08-30131Abbreviated
K222449 ↗Nitrile Powder Free Examination Gloves, Tested For Use With Chemotherapy Drugs And Fentanyl Citrate (Dark Blue)2022-08-15 → 2022-08-2712Traditional
K220545 ↗Powder Free Nitrile Examination Gloves, Blue, Tested for use with Chemotherapy Drugs2022-02-25 → 2022-05-2690Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K243959 · PDF page 6 ↗ Source 2

The glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent
  contamination between patient and examiner.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K243959 · PDF page 6 ↗ Source 2

Powder Free Nitrile Examin ation Gloves (Violet, Black, Green), Tested f           or Use with Chemotherapy Drugs, Fenta n yl
  Citrate and Select Other Drugs Are            Class I P atient Examination Gloves and Specialty Chemotherapy Gloves.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K243959 · PDF page 11 ↗ Source 3

Non-                                          clinical tests were conducted to verify that the proposed device met all design specifications.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Historical references beside dated FDA recognition metadata

Read each mention in the linked original summary, including statements that testing was not performed. Recognition metadata does not determine your testing needs, chosen edition or transition eligibility.

Reference in this historical summaryDesignation in the acquired FDA exportRecognition / entry dateRecorded transition-expiration dateSources
ISO 2859-1
7. Summary of Non-Clinical Performance Data
ISO 2859-1 Second edition 1999-11-15
Sampling procedures for inspection by attributes - Part 1: Sampling schemes indexed by acceptance quality limit (AQL) for lot-by-lot inspection [Including: Technical Corrigendum 1 (2001) Amendment 1 (2011)]
5-88 · Complete
07/09/2014
Not recorded in this export rowSummary [3] · Metadata [4]
Read scope and recognition limits ↗

Prepare for your provider: the proposed protocol/report edition, its justification for your device and the complete current FDA recognition sheet. In particular, inspect exclusions for partial recognition. An edition difference does not automatically make the historical evidence unusable.

Identifier-matching method and selection limits

Match explicit ISO/IEC identifiers in selected preserved summary excerpts to the acquired, count-reconciled FDA metadata export. Preserve the historical edition mention, current snapshot designations, entry dates, recognition extent and any recorded transition-expiration date as separate facts. No title-similarity, edition-equivalence, test-mandate or transition-eligibility inference. At most twenty matched occurrences and thirty metadata rows per reference; wide matches are held for separate review.

1 of 1 matched reference occurrences shown.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK243959 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryPowder Free Nitrile Examination Gloves (Violet, Black, Green), Tested for Use with Chemotherapy Drugs, Fentanyl Citrate and Select Other Drugs [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantLingshi Hongruida Health Protection Technology Co., Ltd. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeLZC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2025-02-24 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2024-12-23 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

  4. Which edition and recognition limits would our provider rely on?

    Compare each historical reference below with the dated FDA metadata. Ask the specialist to justify the applicable scope and selected edition, read the complete supplementary sheet for partial-recognition exclusions, and investigate any recorded transition conditions. A difference in editions does not automatically make the earlier study unusable.

    Useful evidence: Proposed protocol/report edition, dated FDA recognition sheet with scope/exclusions, and a documented edition/transition rationale for the actual device.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[39252] · record 05e9bb525280fdbd3c7c1ab3718ca5db1416762ac3b91576356521643157a4ec
  • [5] Complete results array / fda-decision-context:K243959 · record whole dataset partition

FDA 510(k) summary — K243959 ↗

Wed, 05 Mar 2025 14:50:48 GMT · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 6d75c8de1e96f3784fdca449a0bee6690e8acaaba2ffae1195098b94365390fb

  • [2] PDF page 6 · record c2268f9db037f2327d95862b1529fd1d7ac2752e20234c987dff2ea3b6ad5a19
  • [3] PDF page 11 · record c2f2b3ed26a734a6308c4534b8849f2051ee6454099c4bc19617d2b9bd5af73a

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services